Pentafluorosulfanylbenzoylguanidines of the formula I and II ##STR00001##
in which R1 to R4 have the meanings stated in the claims, are suitable as
antiarrhythmic medicaments with a cardioprotective component for the
prophylaxis of infarction and treatment of infarction and for the
treatment of angina pectoris. They also inhibit preventively the
pathophysiological processes associated with the development of
ischemia-induced damage, especially in the triggering of ischemia-induced
cardiac arrhythmias.